Abbott’s Hep C Drug Trio Cures Most in a Few Months
UPDATE 2-Abbott hepatitis C drugs bring high cure rates in trial
- High cure rates seen in patients treated 8 or 12 weeks
- 93 pct who failed prior drugs cured after 12 weeks
- 97 pct of newly treated patients deemed cured after 12 weeks
- One percent discontinue treatment due to side effects (Adds 100 pct cure rates with Gilead drug in small trial)
By Ransdell Pierson
Nov 10 (Reuters) – A trio of oral medicines from Abbott Laboratories Inc to treat hepatitis C produced unprecedented cure rates in patients who had failed to benefit from standard treatment, as well as very high cure rates for newly treated patients, Abbott said on Saturday.
Detailed data from the mid-stage trial, called Aviator, were released Saturday at the annual meeting of the American Association for the Study of Liver Disease (AASLD) in Boston.
Continue reading this entire article:
Hepatitis C Drug Labeling Update
Hepatitis B Virus Destroyed by Inovio's Vaccine